Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bladder Cancer
  Free Subscription

Articles published in
Int J Urol
    September 2026
  1. FERREIRA WAS, Marchi FA, Vitiello GAF, Villacis RAR, et al
    Cathepsin V (CTSV) Shapes the Epigenetic-Immune Landscape of Bladder Cancer and Emerges as a Noninvasive Biomarker.
    Int J Urol. 2026;33:e70609.
    >> Share

  2. YANAGISAWA T, Matsukawa A, Iwatani K, Hayashida Y, et al
    Perioperative Safety and Long-Term Oncological Outcomes of En Bloc Resection of Bladder Tumor: A Multicenter Real-World Study of 668 Patients.
    Int J Urol. 2026;33:e70634.
    >> Share

  3. OGAWA I, Narita T, Shinohara M, Kawashima Y, et al
    Treatment Patterns and Outcomes After Recurrence Following Adjuvant Nivolumab for Urothelial Carcinoma: An AGEHA Real-World Study.
    Int J Urol. 2026;33:e70636.
    >> Share

    August 2026
  4. MATSUSHITA Y, Kita Y, Mukai S, Joraku A, et al
    Oncological Outcomes and Prognostic Factors of Platinum-Based Chemotherapy Followed by Avelumab Maintenance Therapy Compared With Platinum-Based Chemotherapy Alone: A Propensity Score-Matched Analysis in a Real-World Population.
    Int J Urol. 2026;33:e70584.
    >> Share

  5. WATANABE R
    Editorial Comment to "Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study".
    Int J Urol. 2026;33:e70604.
    >> Share

  6. WAKITA N, Hara T, Tobe T, Ueki H, et al
    Efficacy and Safety of Enfortumab Vedotin by Trial Eligibility in Advanced Urothelial Carcinoma: A Multicenter Real-World Study.
    Int J Urol. 2026;33:e70614.
    >> Share

  7. ALMULLA AF, Zhang Y, Maes M
    Editorial Comment on "Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression": Rethinking the Tryptophan-Kynurenine Pathway in Urological Cancer Immunotherapy.
    Int J Urol. 2026;33:e70606.
    >> Share

    July 2026
  8. KIKUCHI E, Kobayashi T, Shono M, Hoffman J, et al
    Real-World Use of Avelumab First-Line Maintenance for Locally Advanced or Metastatic Urothelial Carcinoma in Japan: Treatment Patterns, Effectiveness, and Safety.
    Int J Urol. 2026;33:e70558.
    >> Share

  9. TAOKA R, Hayakawa N, Kimura T, Kikuchi E, et al
    Consensus-Based Development of a Surgical Checklist for Transurethral Resection of Bladder Tumor: An Initiative of the Japanese Society of Urologic Oncology.
    Int J Urol. 2026;33:e70570.
    >> Share

  10. KIKUCHI E, Tokumaru J, Kawai D, Ide R, et al
    Perioperative Systemic Treatment Patterns and Postoperative Mortality Among Patients With Muscle-Invasive Bladder Cancer Undergoing Radical Cystectomy in Japan: WAKKA-MIBC Study.
    Int J Urol. 2026;33:e70565.
    >> Share

    June 2026
  11. NISHIMURA N, Miyake M, Iwao T, Oda Y, et al
    Sarcopenia Weakens the Benefit of Bacillus Calmette-Guerin in Non-Muscle-Invasive Bladder Cancer: A Computed Tomography-Based Cohort Study.
    Int J Urol. 2026;33:e70526.
    >> Share

  12. KOBAYASHI G, Sekino Y, Miyamoto S, Kobatake K, et al
    Comprehensive Genomic Characterization Between Urothelial Carcinoma Subtypes/Divergent Differentiation (S/DD) and Pure Urothelial Carcinoma Using a Large-Scale Japanese Genomic Panel Dataset.
    Int J Urol. 2026;33:e70538.
    >> Share

  13. ENDO Y, Sakura Y, Kaneko G, Hayakawa N, et al
    Impact of Early Relative Dose Intensity on Survival in Patients Receiving Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Japanese Real-World Multicenter Study.
    Int J Urol. 2026;33:e70523.
    >> Share

  14. IGARASHI A, Kinoshita T, Fujita M, Obayashi R, et al
    Intraoperative Hypotension During Photodynamic Diagnosis-Guided TURBT Under Spinal Anesthesia: A Propensity Score-Matched and Logistic Regression Analysis.
    Int J Urol. 2026;33:e70540.
    >> Share

    May 2026
  15. MIYAKE M
    Editorial Comment to Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
    Int J Urol. 2026;33:e70481.
    >> Share

  16. LEMES DE, Santos AAS, de Oliveira JL, Roman-Ramos H, et al
    Stage-Dependent Changes in Kynurenine Pathway Enzyme Expression Suggest Immune-Related Involvement in Bladder Cancer Progression.
    Int J Urol. 2026;33:e70491.
    >> Share

  17. KAWAHARA T, Nagumo Y, Tanuma K, Hamada K, et al
    Impact of European Association of Urology Combination and Platinum Eligibility on Real-World Treatment Sequences and Survival in Japanese Patients With Metastatic Urothelial Carcinoma.
    Int J Urol. 2026;33:e70403.
    >> Share

  18. LONGONI M, Marmiroli A, Falkenbach F, Le QC, et al
    Extent of Pelvic Lymph Node Dissection at Partial Cystectomy: Effect on Cancer-Specific Mortality.
    Int J Urol. 2026;33:e70483.
    >> Share

  19. MATSUYAMA H
    Reviewer's Comment on Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer.
    Int J Urol. 2026;33:e70499.
    >> Share

    April 2026
  20. FUJITA N
    Editorial Comments to "Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care".
    Int J Urol. 2026;33:e70452.
    >> Share

  21. USUI A, Hara T, Oka S, Sakaguchi K, et al
    Skin Phototoxicity With Aminolevulinic Acid Hydrochloride in Patients With Non-Muscle Invasive Bladder Cancer: Real-World Incidence and Concomitant Medication Effects.
    Int J Urol. 2026;33:e70448.
    >> Share

  22. HATAKEYAMA S, Yamamoto K, Yamamoto H, Yasui T, et al
    Real-World Outcomes After Radical Cystectomy for Muscle-Invasive Bladder Cancer in Japan: A Nationwide Descriptive Study From the National Clinical Database.
    Int J Urol. 2026;33:e70450.
    >> Share

  23. MUTA R, Fukushima H, Tanaka H, Numao N, et al
    Prognostic Significance of Hypoalbuminemia in Maintenance Avelumab Therapy After First-Line Chemotherapy for Metastatic Urothelial Carcinoma: A Multicenter Real-World Study (YUSHIMA Study).
    Int J Urol. 2026;33:e70459.
    >> Share

    March 2026
  24. SANO T, Ohe C, Motoki Y, Nakamoto T, et al
    Prognostic Significance of Tertiary Lymphoid Structure-Like Lymphocyte Aggregates in Routine Histopathological Examination in Bladder Cancer.
    Int J Urol. 2026;33:e70392.
    >> Share

  25. GOTO Y
    Editorial Comment on Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
    Int J Urol. 2026;33:e70405.
    >> Share

  26. SHINOHARA M, Yamamoto H, Kawashima Y, Sekine Y, et al
    Association of Prophylactic Intravenous Corticosteroid Premedication With Toxicity and Survival in Patients Receiving Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Carcinoma.
    Int J Urol. 2026;33:e70425.
    >> Share

    February 2026
  27. SHIMIZU S, Osawa T, Sato M, Yamada S, et al
    Validation of the 7-Item Quality of Life Disease-Specific Impact Scale in Patients Undergoing Radical Cystectomy for Bladder Cancer: A Cross-Sectional Study.
    Int J Urol. 2026;33:e70364.
    >> Share

  28. ABE Y, Taoka R, Kaji A, Harada S, et al
    Efficacy of Photodynamic Diagnosis Is Confined to the Low-Risk Subgroup of Intermediate-Risk Non-Muscle-Invasive Bladder Cancer: A Propensity Score Matched Analysis.
    Int J Urol. 2026;33:e70365.
    >> Share

  29. YAJIMA S, Yoshida S, Chen W, Fukushima H, et al
    Comparison of Perioperative Chemotherapy Regimens for Muscle-Invasive Bladder Cancer: A Reconstructed Individual Patient Data Analysis of Phase 3 Trials.
    Int J Urol. 2026;33:e70380.
    >> Share

  30. KUSANO S, Tobu S, Yukimoto M, Yamaguchi Y, et al
    Palliative Intra-Arterial Chemotherapy Without Radiotherapy for Elderly Patients With Muscle-Invasive Bladder Cancer: A Single-Center Retrospective Comparison With Radical Cystectomy and Best Supportive Care.
    Int J Urol. 2026;33:e70386.
    >> Share

    January 2026
  31. IWASAWA T, Tsujino T, Tsukahara S, Fukushima H, et al
    Translational Advances in Urothelial Carcinoma: From Bench to Bedside.
    Int J Urol. 2026;33:e70341.
    >> Share

  32. HIRATA H
    Editorial Comment on Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2026;33:e70343.
    >> Share

  33. FUJITA N
    Editorial Comments to "Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer".
    Int J Urol. 2026;33:e70358.
    >> Share

  34. SOMA T, Tanaka H, Nakamura Y, Numao N, et al
    Clinical Features and Risk Factors of Enfortumab Vedotin-Induced Peripheral Neuropathy in Patients With Metastatic Urothelial Carcinoma: A Multicenter Retrospective Study (YUSHIMA Study).
    Int J Urol. 2026;33:e70329.
    >> Share

  35. ZAHIR M, Moghadam FS, Ladi-Seyedian SS, Ghoreifi A, et al
    Can Urinary Diversion Type Affect Postoperative Complications Following Radical Cystectomy in Female Patients?
    Int J Urol. 2026;33:e70330.
    >> Share

  36. FUKUTA K, Sasaki Y, Daizumoto K, Izumi K, et al
    Prognostic Significance of Achieving the Radical Cystectomy-Pentafecta After Neoadjuvant Chemotherapy and Robot-Assisted Radical Cystectomy.
    Int J Urol. 2026;33:e70283.
    >> Share

    December 2025
  37. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
    Predictive Factors for Gastrointestinal and Hepatic Adverse Events During 5-Aminolevulinic Acid-Guided Photodynamic Diagnosis in Bladder Cancer: Exploratory Analysis of the Phase III SPP2C102 Trial.
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70328.
    >> Share

  38. FIORENTINO V
    Editorial Comment to "Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Non-Muscular-Invasive Urothelial Bladder Cancer".
    Int J Urol. 2025 Dec 25. doi: 10.1111/iju.70332.
    >> Share

  39. CHEN W, Yoshida S, Ikeda R, Yoshimura R, et al
    Oligometastatic Prostate and Bladder Cancer: An Integrative Narrative Review.
    Int J Urol. 2025 Dec 24. doi: 10.1111/iju.70324.
    >> Share

  40. MIYAKE M, Nishimura N, Taoka R, Miki J, et al
    Real-World Comparison of Survival Outcomes Between Radical Cystectomy and Intravesical Bacillus Calmette-Guerin (BCG) Therapy in BCG-Naive or -Unresponsive Non-Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Dec 12. doi: 10.1111/iju.70314.
    >> Share

  41. SHIOZAKI M, Minagawa T, Yokoyama H, Hirotsu Y, et al
    Prediction of Postoperative Intravesical Recurrence Using Urine DNA Monitoring in Nonmuscular-Invasive Urothelial Bladder Cancer.
    Int J Urol. 2025 Dec 9. doi: 10.1111/iju.70293.
    >> Share

  42. HORI T, Nohara T, Kawahara T, Nakagawa R, et al
    Association Between Preoperative 5-Aminolevulinic Acid Administration Timing and Perioperative Hypotension.
    Int J Urol. 2025;32:1827-1833.
    >> Share

  43. NOMURA N, Sekino Y, Hayashi T, Kobayashi G, et al
    TUBB3 Is Associated With a Poor Prognosis and Basal Subtypes in Upper and Lower Tract Urothelial Carcinoma.
    Int J Urol. 2025;32:1893-1901.
    >> Share

  44. KOBATAKE K, Goto K, Hatayama T, Naito M, et al
    Efficacy of Open-Ended Urinary Catheters in Preventing Catheter-Related Bladder Discomfort: A Randomized Controlled Trial.
    Int J Urol. 2025;32:1819-1826.
    >> Share

    November 2025
  45. MATSUDA K, Tsutsumi M, Kanazawa T, Chihara I, et al
    Limited Response to Enfortumab Vedotin-Pembrolizumab in Three Consecutive Cases of Neoadjuvant Chemotherapy-Resistant Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025;32:1712-1714.
    >> Share

  46. SALAH S, Ito K, Kita Y, Kobayashi T, et al
    Assessing Response Durability and Survival After Second-Line Pembrolizumab in Advanced Urothelial Carcinoma: A Multicenter Validation of a Risk Model.
    Int J Urol. 2025;32:1569-1575.
    >> Share

    October 2025
  47. KUKIMOTO T, Nakamura Y, Hata S, Shimada H, et al
    Expression of Glucocorticoid Receptor Beta in Bladder Cancer and Its Clinicopathological Significance: A Novel Diagnostic Marker to Predict Progression and Recurrence of Cancer.
    Int J Urol. 2025 Oct 15. doi: 10.1111/iju.70254.
    >> Share

  48. INOUE S, Hayakawa A, Kobayashi M, Nagasaka Y, et al
    Response to First-Line Chemotherapy Predicts Response to Maintenance Avelumab Therapy in Japanese Patients With Advanced Urothelial Carcinoma.
    Int J Urol. 2025;32:1449-1459.
    >> Share

  49. AKPINAR C, Erkartal S, Soydas T, Demirel D, et al
    Decision Curve Analysis-Based Risk-Adaptive Strategy for Individualizing Cystoscopy Decisions in Patients With Primary Microscopic Hematuria.
    Int J Urol. 2025;32:1395-1402.
    >> Share

    September 2025

  50. RETRACTION: Astrocyte Elevated Gene-1 Promotes Invasion and Epithelial-Mesenchymal Transition in Bladder Cancer Cells Through Activation of Signal Transducer and Activator of Transcription 3.
    Int J Urol. 2025 Sep 20. doi: 10.1111/iju.70224.
    >> Share

  51. TILLU N, Dovey Z, Choudhary M, Venkatesh A, et al
    Open Versus Robotic Radical Cystectomy With Intracorporeal Neobladder: A Decade-Long Single-Surgeon Experience.
    Int J Urol. 2025;32:1234-1242.
    >> Share

  52. URABE F, Tashiro K, Imai Y, Iwatani K, et al
    Evaluation of Optimal Sequential Treatment Patterns and Clinical Outcomes in Patients With Advanced Urothelial Carcinoma Treated With First-Line Platinum-Based Chemotherapy: A Multicenter Collaborative Study.
    Int J Urol. 2025;32:1147-1156.
    >> Share

    August 2025
  53. KAWAHARA T
    Re: Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Aug 14. doi: 10.1111/iju.70199.
    >> Share

  54. WANG M, Jia B, Yang F, Han S, et al
    The Xing Technique for Intracorporeal Ileal Conduit: Outcomes From a Single Center.
    Int J Urol. 2025;32:1034-1038.
    >> Share

  55. WAKAMIYA T, Yamashita S, Kohjimoto Y, Hara I, et al
    Serum Lactate Dehydrogenase Level Prior to First-Line Chemotherapy for Metastatic Urothelial Carcinoma Is a Prognostic Factor for Avelumab Maintenance Therapy: A Multicenter Retrospective Study.
    Int J Urol. 2025;32:997-1004.
    >> Share

  56. FUKUTA K, Daizumoto K, Sasaki Y, Izumi K, et al
    Geriatric Nutritional Risk Index Predicts Postoperative Complications in Elderly Patients Undergoing Robot-Assisted Radical Cystectomy.
    Int J Urol. 2025;32:944-950.
    >> Share

    July 2025
  57. GOTO Y
    Editorial Comment on "Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer".
    Int J Urol. 2025 Jul 27. doi: 10.1111/iju.70184.
    >> Share

  58. JI J, Guan F, Sun L, Zhang G, et al
    Efficacy of Metastasectomy for Metastatic Bladder Cancer: A Systematic Review and Meta-Analysis.
    Int J Urol. 2025 Jul 9. doi: 10.1111/iju.70176.
    >> Share

  59. KIMURA T, Inoue S, Sano T, Zennami K, et al
    Recent Advances and Future Directions in Bladder Preservation Therapy for Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70164.
    >> Share

  60. MINATO A, Takaba T, Higashijima K, Nagata Y, et al
    Early Experience With Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 Jul 1. doi: 10.1111/iju.70119.
    >> Share

  61. MARUYAMA Y, Sadahira T, Sekito T, Iwasaki Y, et al
    Impact of Early Detection and Varying Duration of Chemoprophylaxis on Venous Thromboembolism After Robot-Assisted Radical Cystectomy.
    Int J Urol. 2025;32:839-847.
    >> Share

    June 2025
  62. YAMAMOTO S, Fukuhara H, Kuroiwa H, Shigehisa R, et al
    Preoperative Pyuria as a Predictor of False-Positive Rates in the Photodynamic Diagnosis of Nonmuscle-Invasive Bladder Cancer Using Oral 5-Aminolevulinic Acid.
    Int J Urol. 2025 Jun 9. doi: 10.1111/iju.70134.
    >> Share

  63. FUKIAGE Y, Muramoto A, Terada N, Kobayashi M, et al
    Peritumoral Infiltration of Regulatory T Cells Reduces the Therapeutic Efficacy of Bacillus Calmette-Guerin Therapy for Bladder Carcinoma In Situ.
    Int J Urol. 2025;32:737-746.
    >> Share

  64. XU S, Shi H, Yu F, Lu M, et al
    Outcomes of Second Resection Following Conventional Initial Transurethral Resection of Bladder Tumors.
    Int J Urol. 2025;32:720-726.
    >> Share

  65. MORGANS AK, Mucha L, Quicquaro C, Shih V, et al
    Treatment Patterns, Healthcare Resource Utilization, and Costs Among Patients Diagnosed With Locally Advanced/Metastatic Urothelial Carcinoma Prior to Receiving Enfortumab Vedotin: A Real-World Evidence Study.
    Int J Urol. 2025;32:650-657.
    >> Share

  66. OZAKI K, Yamamoto H, Sekine Y, Horiguchi H, et al
    Impact of Skin Adverse Events on Prognosis in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Treated With Enfortumab Vedotin: A Real-World Multicenter Study.
    Int J Urol. 2025;32:679-685.
    >> Share

    May 2025
  67. SASAKI D, Yoneyama T, Yoneyama F, Ozaki K, et al
    PD-L1 and Ki-67 Expression Before and After Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer.
    Int J Urol. 2025 May 23. doi: 10.1111/iju.70122.
    >> Share

  68. MIYAKE M
    Editorial Comment From Dr. Miyake to Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
    Int J Urol. 2025 May 15. doi: 10.1111/iju.70112.
    >> Share

  69. AKPINAR C, Suer E, Akdogan B, Izol V, et al
    The effect of neoadjuvant chemotherapy on survival outcomes in patients with variant histologies who underwent radical cystectomy with precystectomy diagnostic accuracy: A multicenter study of the Turkish Urooncology Association.
    Int J Urol. 2025;32:508-515.
    >> Share

  70. YONEYAMA F, Shinohara M, Kawashima Y, Yoneyama A, et al
    Effects of Robot-Assisted Radical Cystectomy on Peritoneal Carcinomatosis and Prognosis in Patients With Muscle-Invasive Bladder Cancer: A Multicenter Retrospective Study.
    Int J Urol. 2025 May 1. doi: 10.1111/iju.70087.
    >> Share

  71. KOBATAKE K, Goto K, Sakamoto Y, Iwane K, et al
    Influence of best objective response to first-line treatment on survival outcomes in advanced urothelial carcinoma in the era of sequential therapy with enfortumab vedotin.
    Int J Urol. 2025;32:524-530.
    >> Share

  72. KANNO T, Ito K, Kita Y, Mochizuki T, et al
    Impact of lymph node dissection during surgery on the efficacy of pembrolizumab in patients with metastatic urothelial carcinoma.
    Int J Urol. 2025;32:593-597.
    >> Share

  73. YAMADA Y, Taguchi M, Shimatani K, Yanagi T, et al
    The usefulness of transarterial embolization before transurethral resection of bladder tumor for patients with large bladder tumors.
    Int J Urol. 2025;32:488-492.
    >> Share

  74. WADA N, Hatakeyama T, Takagi H, Tsunekawa R, et al
    Trends in age and antithrombotic therapy in patients who underwent transurethral resection of bladder tumor and perioperative complications.
    Int J Urol. 2025;32:516-523.
    >> Share

    April 2025
  75. NAITO R, Izumi K, Takimoto A, Nakagawa R, et al
    Does Neoadjuvant Chemotherapy Followed by Radical Cystectomy Improve the Survival of Muscle-Invasive Bladder Cancer in Real-World Clinical Practice?
    Int J Urol. 2025 Apr 11. doi: 10.1111/iju.70064.
    >> Share

  76. SIMHAL RK, McPartland C, Wang KR, Buck M, et al
    Bowel regimens before radical cystectomy: An analysis of a modern cohort.
    Int J Urol. 2025;32:402-408.
    >> Share

    March 2025
  77. SANO T, Ohe C, Nakamoto T, Yoshida T, et al
    Pathological Analysis of False-Positive Samples in Photodynamic Diagnosis of Bladder Cancer According to a History of Intravesical Bacillus Calmette-Guerin Therapy.
    Int J Urol. 2025 Mar 26. doi: 10.1111/iju.70045.
    >> Share

  78. YAJIMA S, Hata S, Masumori N, Matsuoka Y, et al
    Patient Preferences for Post-Radical Cystectomy Treatment in Muscle-Invasive Bladder Cancer: A Discrete Choice Experiment in Japan.
    Int J Urol. 2025 Mar 10. doi: 10.1111/iju.70032.
    >> Share

  79. SAZUKA T
    Editorial Comment to "Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Nonmuscle Invasive Bladder Cancer".
    Int J Urol. 2025 Mar 3. doi: 10.1111/iju.70028.
    >> Share

  80. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
    Int J Urol. 2025;32:270-276.
    >> Share

    February 2025
  81. SHINDO T, Ueki Y, Muranaka I, Kobayashi G, et al
    Differential Risk Factors for Early Intravesical Recurrence After Radical Nephroureterectomy for Upper Urinary Tract Carcinoma According to the History of Non-Muscle Invasive Bladder Cancer.
    Int J Urol. 2025 Feb 13. doi: 10.1111/iju.70009.
    >> Share

  82. HARA S, Fukuokaya W, Miki J, Taoka R, et al
    Stage III substaging and outcomes in patients with bladder cancer undergoing radical cystectomy.
    Int J Urol. 2025 Feb 5. doi: 10.1111/iju.70005.
    >> Share

    January 2025
  83. MIYAKE M
    Editorial Comment from Dr Miyake to alpha1-blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2025 Jan 28. doi: 10.1111/iju.15687.
    >> Share

  84. SUZUKI C, Minagawa T, Onuma H, Hiragata S, et al
    alpha(1)-Blockers as a risk factor for hypotension in combination with oral 5-aminolevulimic acid for photodynamic diagnosis in patients with bladder cancer.
    Int J Urol. 2025 Jan 3. doi: 10.1111/iju.15655.
    >> Share

    December 2024
  85. TAOKA R, Fujimoto K, Inoue K, Tsuzuki T, et al
    Accuracy of photodynamic diagnosis for non-muscle-invasive bladder cancer: Exploratory analysis of anatomical locations and tumor types using data from a prospective, single-arm, multicenter phase III trial.
    Int J Urol. 2024 Dec 13. doi: 10.1111/iju.15653.
    >> Share

  86. NAKAMURA Y, Yoshida S, Arita Y, Takeshita R, et al
    The need for a second transurethral resection in high-risk non-muscle-invasive bladder cancer based on the Vesicle Imaging-Reporting and Data System.
    Int J Urol. 2024 Dec 9. doi: 10.1111/iju.15638.
    >> Share

  87. PALERMO G, Bizzarri FP, Scarciglia E, Sacco E, et al
    The mental and emotional status after radical cystectomy and different urinary diversion orthotopic bladder substitution versus external urinary diversion after radical cystectomy: A propensity score-matched study.
    Int J Urol. 2024;31:1423-1428.
    >> Share

  88. SASAKI Y, Fukuta K, Kadoriku F, Daizumoto K, et al
    Retroperitoneal cutaneous ureterostomy following radical cystectomy: A multicenter comparative study of robotic versus open surgery.
    Int J Urol. 2024;31:1408-1413.
    >> Share

  89. MORIZANE S, Miki J, Shimbo M, Kanno T, et al
    Japanese expert consensus on the standardization of robot-assisted pelvic lymph node dissection in urological surgery: Extent of pelvic lymph node and surgical technique.
    Int J Urol. 2024;31:1300-1310.
    >> Share

    November 2024
  90. NAKAMURA Y, Ishikawa Y, Kobayashi M, Fujiwara M, et al
    Location-specific diagnostic efficiency of photodynamic diagnosis-guided biopsy in bladder mapping biopsies.
    Int J Urol. 2024;31:1263-1268.
    >> Share

  91. YOSHIDA S, Maezawa Y, Ishihara K, Inoue N, et al
    Outcomes and prognostic factors in patients with synchronous and metachronous oligometastatic urothelial carcinoma with visceral metastases.
    Int J Urol. 2024;31:1234-1240.
    >> Share

    October 2024
  92. HARA T, Suzuki K, Okada K, Chiba K, et al
    Comparative clinical trials with a novel approach: Utilizing the shiny method for investigational urothelial carcinoma therapies.
    Int J Urol. 2024;31:1168-1170.
    >> Share

    September 2024
  93. FUKUOKAYA W, Miki J, Taoka R, Saito R, et al
    Development and validation of a model to predict the outcomes of radical cystectomy in patients with bladder cancer.
    Int J Urol. 2024 Sep 18. doi: 10.1111/iju.15585.
    >> Share

    August 2024
  94. YAMANE H, Morizane S, Honda M, Muraoka K, et al
    Preoperative risk stratification models after radical cystectomy for bladder cancer: A multi-center study.
    Int J Urol. 2024 Aug 14. doi: 10.1111/iju.15560.
    >> Share

  95. GIUDICE GC, Sonpavde GP
    Editorial Comment on "Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey".
    Int J Urol. 2024;31:943-944.
    >> Share

  96. CHENG LJ, Kim J, Mukherjee A, Milloy N, et al
    Real-world treatment patterns and quality of life among patients with locally advanced or metastatic urothelial carcinoma living in Saudi Arabia, South Korea, Taiwan, and Turkey.
    Int J Urol. 2024;31:933-943.
    >> Share

  97. SHINDO T
    Editorial Comment to J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Int J Urol. 2024;31:867-868.
    >> Share

  98. KIKUCHI E, Hayakawa N, Nakayama M, Uno M, et al
    J-AVENUE: A retrospective, real-world study evaluating patient characteristics and outcomes in patients with advanced urothelial carcinoma treated with avelumab first-line maintenance therapy in Japan.
    Int J Urol. 2024;31:859-867.
    >> Share

  99. TAOKA R, Sugimoto M
    A surgical checklist for optimizing the quality and outcomes of transurethral resection of bladder tumors: A literature review.
    Int J Urol. 2024;31:846-851.
    >> Share

  100. NOHARA T, Takimoto A, Shinzawa R, Kurauchi D, et al
    Comprehensive analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of bladder tumor with 5-aminolevulinic acid.
    Int J Urol. 2024;31:891-898.
    >> Share

    July 2024
  101. URABE F, Suzuki H, Iwatani K, Kimura T, et al
    Editorial Comment on "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15537.
    >> Share

  102. KIKUCHI E, Hayakawa N
    Editorial Comment to "Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer".
    Int J Urol. 2024 Jul 16. doi: 10.1111/iju.15541.
    >> Share

  103. HATTORI Y, Fujiwara T, Hagimoto H, Kokubun H, et al
    Efficacy and safety of dose-dense gemcitabine plus cisplatin as neoadjuvant chemotherapy for muscle-invasive bladder cancer.
    Int J Urol. 2024 Jul 3. doi: 10.1111/iju.15524.
    >> Share

  104. YASUDA Y, Numao N, Fujiwara R, Takemura K, et al
    Surgical outcomes and predictive value for major complications of robot-assisted radical cystectomy of real-world data in a single institution in Japan.
    Int J Urol. 2024;31:724-729.
    >> Share

  105. ASAKAWA K, Waratani M, Massey O, Holbrook T, et al
    Real-world epidemiology and treatment patterns of patients with locally advanced or metastatic urothelial carcinoma: Retrospective analysis of Diagnosis Procedure Combination claims data in Japan.
    Int J Urol. 2024;31:730-738.
    >> Share

    June 2024
  106. FU H, Hillman E, Talluri S, Liang L, et al
    Comparison of the perioperative outcomes of using the Firefly system with indocyanine green during robotic-assisted cystectomy with urinary diversion.
    Int J Urol. 2024;31:646-652.
    >> Share

  107. HARA T, Matsushita Y, Harada K, Fujimoto N, et al
    Clinical outcomes in patients with advanced urothelial carcinoma treated with enfortumab vedotin: A retrospective multicenter study in Japan.
    Int J Urol. 2024;31:696-698.
    >> Share

  108. UEMURA K, Ito H, Jikuya R, Kondo T, et al
    Enfortumab vedotin prolongs overall survival in metastatic urothelial carcinoma following pembrolizumab therapy in real-world data.
    Int J Urol. 2024;31:678-684.
    >> Share

  109. NAKAGAWA R, Izumi K, Toriumi R, Aoyama S, et al
    Does radical cystectomy have a better prognosis than bladder conservative treatment in the real world?
    Int J Urol. 2024;31:628-636.
    >> Share

    May 2024
  110. MITSUI Y, Okawa M, Hori S, Uetani M, et al
    Effectiveness of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin as compared to gemcitabine-based regimens as neoadjuvant chemotherapy for oncologic outcomes in muscle-invasive bladder cancer cases-Single-center study in Japan.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15509.
    >> Share

  111. MIKI J, Fukuokaya W, Taoka R, Saito R, et al
    Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.
    Int J Urol. 2024 May 31. doi: 10.1111/iju.15505.
    >> Share

  112. HAYAKAWA N, Kikuchi E
    Editorial Comment on "Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification
    Int J Urol. 2024 May 16. doi: 10.1111/iju.15495.
    >> Share

  113. MIYAKE M
    Editorial Comment from Dr Miyake to Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node
    Int J Urol. 2024 May 3. doi: 10.1111/iju.15487.
    >> Share

  114. KAWAI T, Matsuyama H, Kobayashi K, Ikeda A, et al
    Photodynamic diagnosis-assisted transurethral resection of bladder tumor for high-risk non-muscle invasive bladder cancer improves intravesical recurrence-free survival (BRIGHT study).
    Int J Urol. 2024 May 2. doi: 10.1111/iju.15483.
    >> Share

  115. KONDO T
    Editorial Comment to Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:560-561.
    >> Share

  116. ISHIHARA H, Takagi T
    Editorial Comment on Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:559-560.
    >> Share

  117. KITA Y, Otsuka H, Ito K, Hara T, et al
    Real-world sequential treatment patterns and clinical outcomes among patients with advanced urothelial carcinoma in Japan.
    Int J Urol. 2024;31:552-559.
    >> Share

  118. TANAKA T, Yamasaki K, Nofuji S, Maehana T, et al
    Development and preliminary evaluation of a novel procedure for creation of an ileal conduit stoma aimed at preventing parastomal hernia.
    Int J Urol. 2024;31:512-518.
    >> Share

    April 2024
  119. MIYAKE M, Nishimura N, Nakahama T, Nishimoto K, et al
    Differences in oncological benefits from second transurethral resection between white-light initial surgery and photodynamic diagnosis-guided initial surgery for primary high-risk non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15474.
    >> Share

  120. SHIOTA M, Nagakawa S, Tsukahara S, Matsumoto T, et al
    Independent validation of genetic risk model to progression after intravesical bacillus Calmette-Guerin therapy for non-muscle invasive bladder cancer.
    Int J Urol. 2024 Apr 30. doi: 10.1111/iju.15484.
    >> Share

  121. SAKURA Y, Yamashita R, Notsu A, Usui K, et al
    Effectiveness of adjuvant chemotherapy for patients who undergo radical cystectomy without neoadjuvant chemotherapy: A retrospective cohort study of 115 advanced bladder cancer patients with pathological lymph node classification.
    Int J Urol. 2024 Apr 12. doi: 10.1111/iju.15465.
    >> Share

  122. LUO HL
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:421.
    >> Share

  123. TAOKA R, Sugimoto M
    Editorial Comment on Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:418-419.
    >> Share

  124. HIYAMA Y
    Editorial comment to Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:437.
    >> Share

  125. URABE F
    Letter to the Editor Re: Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:420.
    >> Share

  126. HAYAKAWA N, Kikuchi E
    Editorial comment to "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:402-403.
    >> Share

  127. SAZUKA T
    Editorial Comment on "The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study".
    Int J Urol. 2024;31:401-402.
    >> Share

  128. TAGUCHI S
    Editorial comment from Dr Taguchi to Real world evidence of enfortumab vedotin in patients with advanced urothelial cancer: A multicenter observational study.
    Int J Urol. 2024;31:348.
    >> Share

  129. SOWANTHIP D, Zennami K, Bejrananda T, Nukaya T, et al
    Older versus younger patients in robot-assisted radical cystectomy with intracorporeal ileal conduit comparing safety and clinical outcomes.
    Int J Urol. 2024;31:370-378.
    >> Share

  130. KAMEI J, Endo K, Yamazaki M, Sugihara T, et al
    Lower bleeding volume contributes to decreasing surgical site infection in radical cystectomy: A propensity score-matched comparison of open versus robot-assisted radical cystectomy.
    Int J Urol. 2024;31:430-437.
    >> Share

  131. SASAHARA T, Yanagisawa T, Sugaya S, Hisakane A, et al
    Prognostic factors for overall survival in clinical node-positive patients with upper tract urothelial carcinoma.
    Int J Urol. 2024;31:386-393.
    >> Share

  132. YU TY, Wang HJ, Sung MT, Chuang YC, et al
    Variant histology is associated with more non-urothelial tract recurrence but less intravesical recurrence for upper tract urothelial carcinoma after radical nephroureterectomy.
    Int J Urol. 2024;31:410-418.
    >> Share

  133. NAKANO J, Urabe F, Kiuchi Y, Takamizawa S, et al
    The clinical impact of ureteroscopy for upper tract urothelial carcinoma: A multicenter study.
    Int J Urol. 2024;31:394-401.
    >> Share

  134. URABE F, Ito K, Kimura T
    Letter to the Editor Re: Balancing diagnostic advancements with cardiovascular considerations in 5-aminolevulinic acid use for bladder tumors.
    Int J Urol. 2024;31:452.
    >> Share

    March 2024
  135. MORI K, Hatakeyama S, Enokida H, Miyake H, et al
    Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
    Int J Urol. 2024;31:194-207.
    >> Share

  136. ISHIKAWA Y, Tanaka H, Fujiwara M, Nakamura Y, et al
    Incidence and predictors of intraoperative hypotension during transurethral bladder tumor resection with oral 5-aminolevulinic acid.
    Int J Urol. 2024;31:238-244.
    >> Share

  137. MATSUKAWA A, Morizane S, Shimizu R, Teraoka S, et al
    Chronic kidney disease and Charlson comorbidity index predict complications after robot-assisted radical cystectomy: A single-center study in Japan.
    Int J Urol. 2024;31:231-237.
    >> Share

    February 2024
  138. KONDO T
    Editorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:133.
    >> Share

  139. SUHARA Y, Urabe F, Yoshihara K, Kurawaki S, et al
    Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
    Int J Urol. 2024;31:125-132.
    >> Share

    January 2024
  140. UKIMURA O
    Editorial Comment on Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 10. doi: 10.1111/iju.15392.
    >> Share

  141. TSUKUDA F, Tanaka Y, Narita S, Shimizu T, et al
    Does intensity-modulated radiation therapy by helical tomotherapy for prostate cancer increase the subsequent risk of bladder cancer? A propensity score-matched analysis.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15373.
    >> Share

  142. NAGAKAWA S, Shiota M, Takamatsu D, Tsukahara S, et al
    Clinical features and oncological outcomes of bladder cancer microsatellite instability.
    Int J Urol. 2024 Jan 9. doi: 10.1111/iju.15370.
    >> Share

  143. NAKAMOTO T, Yoshida T
    Response to Comment: Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:90.
    >> Share

  144. MORI K, Yanagisawa T, Fukuokaya W, Iwatani K, et al
    Adjuvant immunotherapy in patients with renal cell carcinoma and urothelial carcinoma: A systematic review and network meta-analysis.
    Int J Urol. 2024;31:25-31.
    >> Share

  145. KIKUCHI E, Ng CF, Kitamura H, Ku JH, et al
    Controversies in terminology associated with management of BCG-unresponsive NMIBC in Asia-Pacific.
    Int J Urol. 2024;31:32-38.
    >> Share

  146. JUE JS, Alameddine M, Armenakas NA
    Future goals of upper tract urothelial carcinoma endoscopic management.
    Int J Urol. 2024;31:89.
    >> Share

    December 2023
  147. GOTO Y
    Editorial Comment on Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15360.
    >> Share

  148. ARAI S
    Editorial Comment on Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Dec 10. doi: 10.1111/iju.15361.
    >> Share

  149. HASHIMOTO T
    Editorial Comment to Enfortumab vedotin versus platinum rechallenge in post-platinum post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1186-1187.
    >> Share

  150. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Enfortumab vedotin versus platinum rechallenge in post-platinum, post-pembrolizumab advanced urothelial carcinoma: A multicenter propensity score-matched study.
    Int J Urol. 2023;30:1180-1186.
    >> Share

  151. KATO M, Uchida J
    Recent advances in immune checkpoint inhibitors in the treatment of urothelial carcinoma: A review.
    Int J Urol. 2023;30:1068-1077.
    >> Share

    November 2023
  152. TOMIYAMA E, Fujita K, Hashimoto M, Uemura H, et al
    Urinary markers for bladder cancer diagnosis: A review of current status and future challenges.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15338.
    >> Share

  153. ROSAZZA M, Soria F, Gontero P
    Editorial comment-Risk stratification and management of nonmuscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Nov 15. doi: 10.1111/iju.15340.
    >> Share

  154. NUNES FM, Apolonio JD, Mota-Pinto A, Leao R, et al
    Epigenetic alterations in urothelial bladder cancer associated with disease outcomes.
    Int J Urol. 2023 Nov 14. doi: 10.1111/iju.15335.
    >> Share

  155. MORI K
    Editorial Comment from Dr. Mori to texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1059.
    >> Share

  156. CHEN W, Yokoyama M, Waseda Y, Kobayashi M, et al
    Surgical outcomes of robot-assisted radical cystectomy in octogenarian or older patients: A Japanese nationwide study.
    Int J Urol. 2023;30:1014-1019.
    >> Share

  157. KANEKO H, Fujiwara M, Tanaka H, Kimura K, et al
    Texture feature analysis using dynamic computed tomography for preoperative risk stratification in upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:1056-1058.
    >> Share

    October 2023
  158. KU JH, Lee LS, Lin TP, Kikuchi E, et al
    Risk stratification and management of non-muscle-invasive bladder cancer: A physician survey in six Asia-Pacific territories.
    Int J Urol. 2023 Oct 6. doi: 10.1111/iju.15309.
    >> Share

  159. SHIGETA K
    Editorial Comments to "Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort".
    Int J Urol. 2023;30:859.
    >> Share

  160. TABATA H, Tanaka T, Shindo T, Hashimoto K, et al
    Urethrectomy via parapenile incision to complete robot-assisted radical cystectomy in a spine position for male patients.
    Int J Urol. 2023;30:936-938.
    >> Share

  161. SOMIYA S, Kobori G, Ito K, Nakagawa H, et al
    Preoperative risk classification for intravesical recurrence after laparoscopic radical nephroureterectomy for upper tract urothelial carcinoma in a multi-institutional cohort.
    Int J Urol. 2023;30:853-858.
    >> Share

    September 2023
  162. KIKUCHI E, Hayakawa N
    Editorial Comment to "Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study".
    Int J Urol. 2023 Sep 27. doi: 10.1111/iju.15311.
    >> Share

  163. FUKUSHIMA H
    Editorial Comment to Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Sep 22. doi: 10.1111/iju.15308.
    >> Share

  164. SZARVAS T
    Editorial Comment to Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15296.
    >> Share

  165. SATO T, Sano T, Kawamura S, Ikeda Y, et al
    Improving compliance with guidelines may lead to favorable clinical outcomes for patients with non-muscle-invasive bladder cancer: A retrospective multicenter study.
    Int J Urol. 2023 Sep 4. doi: 10.1111/iju.15294.
    >> Share

  166. KIKUCHI E, Hayakawa N
    Editorial Comment to "The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion".
    Int J Urol. 2023;30:786-787.
    >> Share

  167. HARA T, Furukawa J, Okamura Y, Bando Y, et al
    The poor antitumor effect of pembrolizumab in advanced upper urothelial carcinoma with renal parenchymal invasion.
    Int J Urol. 2023;30:779-786.
    >> Share

  168. TOMISAKI I, Harada M, Sakano S, Terado M, et al
    Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.
    Int J Urol. 2023;30:738-745.
    >> Share

  169. ITO K, Kita Y, Kobayashi T
    Real-world outcomes of pembrolizumab for platinum-refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:696-703.
    >> Share

  170. GOTO Y
    Editorial comment to real-world outcomes of pembrolizumab for platinum refractory advanced urothelial carcinoma: Efficacy, safety, and evidence for trial-unfit patients.
    Int J Urol. 2023;30:704.
    >> Share

    August 2023
  171. GOTO Y
    Editorial Comment to Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15286.
    >> Share

  172. NISHIMURA N, Miyake M, Nakahama T, Miyamoto T, et al
    Impact on Japanese healthcare economics of photodynamic diagnosis-assisted transurethral resection of bladder tumor for non-muscle invasive bladder cancer: A multicenter retrospective cohort study.
    Int J Urol. 2023 Aug 22. doi: 10.1111/iju.15283.
    >> Share

  173. LIANG HQ, Liao NK, Yang SB, Wei QJ, et al
    Identification of tumor immunophenotypes associated with immunotherapy response in bladder cancer.
    Int J Urol. 2023 Aug 21. doi: 10.1111/iju.15276.
    >> Share

  174. GOTO Y
    Editorial Comment to Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:647-648.
    >> Share

  175. YOSHIDA T, Ohe C, Nakamoto T, Kinoshita H, et al
    Learning from the past and present to change the future: Endoscopic management of upper urinary tract urothelial carcinoma.
    Int J Urol. 2023;30:634-647.
    >> Share

  176. KONDO T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:657.
    >> Share

  177. SAZUKA T
    Editorial Comment to Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:658.
    >> Share

  178. OKUYAMA Y, Hatakeyama S, Tabata R, Fujimori D, et al
    Impact of nephroureterectomy on postoperative renal function in upper tract urothelial carcinoma: A multicenter retrospective study.
    Int J Urol. 2023;30:649-657.
    >> Share

    July 2023
  179. MIYAKE M, Nishimura N, Fujii T, Fujimoto K, et al
    Recent advancements in the diagnosis and treatment of non-muscle invasive bladder cancer: Evidence update of surgical concept, risk stratification, and BCG-treated disease.
    Int J Urol. 2023 Jul 31. doi: 10.1111/iju.15263.
    >> Share

  180. HAGIMOTO H, Kambe T, Mine Y, Kokubun H, et al
    Necessity of prophylactic drainage tube in retroperitoneal laparoscopic nephroureterectomy with open distal ureterectomy: A matched-pair analysis.
    Int J Urol. 2023;30:579-584.
    >> Share

  181. ISHII N, Hatakeyama S, Miura H, Tanaka R, et al
    Trends in the age of hospitalized patients with urological cancers: A 17-year experience.
    Int J Urol. 2023;30:572-578.
    >> Share

    May 2023
  182. LIU Z, Leow JJ, Yong DZP
    Editorial Comment to Significance of dorsal bladder neck involvement in predicting the progression of non-muscle-invasive bladder cancer.
    Int J Urol. 2023 May 10. doi: 10.1111/iju.15200.
    >> Share

  183. CHOO ZW, Leow JJ, Vong E, Chia PL, et al
    Editorial Comment to Impact of the coronavirus disease-2019 pandemic on the number of patients undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospect
    Int J Urol. 2023;30:471-472.
    >> Share

  184. TSURUTA K, Majima T, Nishikimi T, Kashima A, et al
    Impact of the coronavirus disease 2019 pandemic on the number of undergoing radical nephroureterectomy and postoperative adjuvant systematic therapy for upper tract urothelial carcinomas in Japan: A multicenter retrospective study.
    Int J Urol. 2023;30:464-471.
    >> Share

    April 2023
  185. MASTROIANNI R, Torregiani G, Simone G
    Editorial Comment on Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:373-374.
    >> Share

  186. TAFURI A, Panunzio A, Gozzo A, Ornaghi PI, et al
    Impact of functional impairment and cognitive status on perioperative outcomes and costs after radical cystectomy: The role of Barthel Index.
    Int J Urol. 2023;30:366-373.
    >> Share

    March 2023
  187. MATSUMOTO K
    Editorial Comment on Validation of the risk stratification newly defined in the Japanese Urological Association guidelines 2019 for non-muscle invasive bladder cancer: A multi-institutional collaborative study.
    Int J Urol. 2023 Mar 16. doi: 10.1111/iju.15177.
    >> Share

  188. MOEEN AM
    Editorial Comment on Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter-related bladder discomfort in TURBT: A randomized, double-blind, controlled trial.
    Int J Urol. 2023;30:270-271.
    >> Share

  189. CHEN W, Yokoyama M, Kobayashi M, Fan B, et al
    Trends of radical cystectomy and comparisons of surgical outcomes among surgical approaches focusing on robot-assisted radical cystectomy: A Japanese nationwide database study.
    Int J Urol. 2023;30:258-263.
    >> Share

  190. MIYAKE M, Oda Y, Nishimura N, Shimizu T, et al
    Chemotherapy with gemcitabine and cisplatin downregulates tumor expression level of nectin-4 in a syngeneic model of murine MBT2 urothelial cancer cell line and C3H mice.
    Int J Urol. 2023;30:328-330.
    >> Share

  191. SINGH A, Kayina CA, Naik N, Ganesh V, et al
    Transurethral lidocaine (100 mg) bladder irrigation (TULI100) reduces the incidence of catheter related bladder discomfort in transurethral resection of bladder tumors: A randomized, double blind, controlled trial.
    Int J Urol. 2023;30:264-270.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016